For the quarter ending 2026-03-31, GOSS had $3,296K increase in cash & cash equivalents over the period. -$38,721K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net realized gain on investments | - | 5 | - | - |
| Loss on disposal of property and equipment | - | 0 | 0 | 0 |
| Net loss | -46,664 | -47,238 | -48,221 | -74,911 |
| Depreciation and amortization expense | 5 | 6 | 6 | 12 |
| Stock-based compensation expense | 6,304 | 2,898 | 2,666 | 4,991 |
| In process research and development expenses | - | -1 | 7,476 | - |
| Amortization of operating lease right-of-use assets | 227 | 221 | 214 | 543 |
| Amortization of long-term debt discount and issuance costs | 255 | 251 | 248 | 486 |
| Amortization of premium on marketable securities, net of accretion of discounts | 660 | 1,082 | 1,585 | 4,611 |
| Receivable from contracts with collaborators | -2,975 | 2,984 | 1,664 | 2,241 |
| Prepaid expenses and other current assets | -2,416 | 3,963 | -879 | 5,369 |
| Other assets | -10 | 1 | 24 | 100 |
| Operating lease liabilities | 227 | 222 | 205 | 534 |
| Accounts payable | 6,156 | 4,822 | -795 | -6,774 |
| Accrued expenses and other current liabilities | -234 | -223 | 1,308 | 363 |
| Accrued research and development expenses | -4,267 | 3,926 | 2,135 | 5,146 |
| Accrued compensation and benefits | 1,435 | -759 | 2,809 | -2,834 |
| Contract liabilities | -8,952 | -1,460 | -3,914 | -952 |
| Accrued interest expense | 2,500 | -2,500 | 2,500 | 0 |
| Net cash used in operating activities | -38,721 | -48,314 | -36,167 | -86,785 |
| Purchase of marketable securities | 24,994 | 20,988 | 29,586 | 176,533 |
| Maturities of marketable securities | 66,600 | 87,000 | 46,600 | 242,800 |
| Sales of marketable securities | - | 7,144 | - | - |
| Purchase of property and equipment | 0 | 0 | 0 | 79 |
| Proceeds from the exercise of warrants | - | 2,717 | 938 | - |
| Net cash provided by investing activities | 41,606 | 73,156 | 17,014 | 66,188 |
| Proceeds from grant of equity option pursuant to chiesi collaboration agreement | - | - | 0 | 0 |
| Proceeds from issuance of equity option pursuant to stock purchase agreement | - | 0 | - | - |
| Principal repayments of long-term debt | - | 0 | 0 | 0 |
| Proceeds from issuance of common stock and warrants in a private offering, net of offering costs | - | 0 | - | - |
| Proceeds from issuance of common stock pursuant to employee stock purchase plan | 292 | -1 | 469 | 372 |
| Proceeds from the exercise of stock options | 220 | 1,239 | 465 | 226 |
| Net cash provided by financing activities | 512 | 3,955 | 1,872 | 598 |
| Effect of exchange rate changes on cash and cash equivalents | -101 | 2 | -95 | 234 |
| Net increase (decrease) in cash and cash equivalents | 3,296 | 28,799 | -17,376 | -19,765 |
| Cash and cash equivalents, at the beginning of the period | 37,732 | 8,933 | 46,074 | - |
| Cash and cash equivalents, at the end of the period | 41,028 | 37,732 | 8,933 | - |
Gossamer Bio, Inc. (GOSS)
Gossamer Bio, Inc. (GOSS)